Could a lower dose of burosumab work just as well for XLH?
NCT ID NCT07183579
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 34 times
Summary
XLH is a rare genetic condition that causes low phosphate levels, leading to weak bones and pain. Burosumab is a standard treatment, but the best starting dose is still unclear. This study will review the medical records of 120 children across England to see if a lower dose (under 0.8 mg/kg) can still control phosphate levels effectively. The goal is to find the safest, most effective dose for each child.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for X-LINKED HYPOPHOSPHATEMIA (XLH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nottingham University Hospitals NHS Trust
RECRUITINGNottingham, NG7 2UH, United Kingdom
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
burosumab (Crysvita)
What this could lead to
If successful, this study could help doctors choose the lowest effective dose of burosumab for children with XLH, reducing unnecessary high-dose exposure while still controlling phosphate levels.
What could go wrong
This is an observational study that only looks back at existing medical records, so it cannot prove cause and effect. Results may vary across different clinics and may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.